|
Mar 7
|
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Mar 5
|
H.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might reveal
|
|
Mar 3
|
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
|
|
Feb 27
|
Cassava Sciences Licenses Simufilam Method of Treatment Patent
|
|
Feb 21
|
Cassava Gears Up to Report Q4 Earnings: What's in the Cards?
|
|
Sep 30
|
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims
|
|
Sep 30
|
Company News for Sep 30, 2024
|
|
Sep 27
|
Why Cassava Sciences Stock Dived by Almost 11% Today
|
|
Sep 27
|
These Stocks Moved the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More
|
|
Sep 27
|
Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims
|
|
Sep 27
|
Top Midday Decliners
|
|
Sep 27
|
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims
|
|
Sep 27
|
Cassava Sciences shares drop in pre-open trade after $40 mln SEC settlement
|
|
Sep 27
|
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
|
|
Sep 27
|
Update: Cassava Sciences Pays $40 Million to Settle SEC Charges; Shares Drop Pre-Bell
|
|
Sep 26
|
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
|
|
Sep 26
|
Cassava Sciences Resolves SEC Investigation
|
|
Sep 26
|
Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims
|
|
Sep 25
|
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
|
|
Sep 3
|
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
|